Search Results
Showing 1 of 1 results
‘Our goal is to lead the field of biosimilars, just like we lead in generic medicines’
Dr. Nir Shapir, VP of Teva’s global research and development team and CMC Biosimilars division, discusses Teva’s entry into the biosimilars market and the complexity of manufacturing biopharmaceuticals. Read the interview with Haaretz (reprinted with permission)
